Eteplirsen: First Global Approval.

Eteplirsen: First Global Approval.

Item
http://www.wikidata.org/entity/Q38997220
The golden retriever model of Duchenne muscular dystrophy.Targeting Splicing in the Treatment of Human DiseaseMoving towards successful exon-skipping therapy for Duchenne muscular dystrophy.Developing multidisciplinary clinics for neuromuscular care and research.Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy.Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro.Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.Contrast-Enhanced Near-Infrared Optical Imaging Detects Exacerbation and Amelioration of Murine Muscular Dystrophy.Impact, Characterization, and Rescue of Pre-mRNA Splicing Mutations in Lysosomal Storage Disorders.A dystrophic Duchenne mouse model for testing human antisense oligonucleotides.A license to cure?Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases.Characteristics of Japanese Patients with Becker Muscular Dystrophy and Intermediate Muscular Dystrophy in a Japanese National Registry of Muscular Dystrophy (Remudy): Heterogeneity and Clinical Variation.
P2860

Eteplirsen: First Global Approval.

Item
http://www.wikidata.org/entity/Q38997220
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Eteplirsen: First Global Approval.
@en
type
label
Eteplirsen: First Global Approval.
@en
prefLabel
Eteplirsen: First Global Approval.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P356
P1433
P1476
Eteplirsen: First Global Approval.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698